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eter van der Meer, MD, PHD,
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irk J. van Veldhuisen, MD, PHD
roningen, the Netherlands
nemia is commonly observed in patients with renal failure
nd chronic heart failure (HF). Its presence is associated
ith a lower quality of life and an impaired survival (1). As
logical next step it was thought that correction of anemia
ould result in an improved outcome. Although erythro-
oietin (EPO) has been successfully used in clinical practice
or more than 2 decades, the relationships among anemia,
PO treatment, and outcome seems to be more complex
han first thought. A meta-analysis by Phrommintikul et al.
2) showed that EPO treatment in anemic patients with
enal failure, which was targeted to achieve higher hemo-
lobin values, was associated with increased mortality and
See page 1949
igher risk of hypertension and thrombosis. Recently pub-
ished results of the TREAT (Trial to Reduce Cardiovas-
ular Events with Aranesp Therapy) study only emphasized
hese concerns (3). In this phase III clinical trial, 4,038
atients with diabetes, chronic kidney disease, and anemia
ere randomly assigned to darbepoetin alfa (a long-acting
rythropoietin analogue) to achieve a hemoglobin level of
pproximately 13 g/dl or placebo, with rescue darbepoetin
lfa when the hemoglobin levels dropped below 9.0 g/dl.
arbepoetin alfa administration did not reduce the com-
osite end point of death or a cardiovascular event. More-
ver, it was associated with an increased risk of stroke
hazard ratio: 1.92, 95% confidence interval: 1.38 to 2.68,
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eported that they have no relationships to disclose. 0.001). It has been postulated that the increased
iscosity or hypertension related to EPO use might be
nvolved.
It has been shown that EPO also harbors, besides direct
ematopoietic effects, pleiotropic effects beyond correcting
nemia (4). The EPO receptor has been detected in several
on-hematopoietic tissues, including brain and heart (5,6).
tudies have shown that EPO treatment improves cardiac
unction in experimental heart failure. However, hemoglo-
in levels do increase and might in part offset the beneficial
ffects of EPO, related to increased viscosity and hyperten-
ion. One possibility to avoid hematopoiesis is to use a low
ose of EPO. Previously, it has been shown that tissue
rotection in the heart is achieved even with a low dose of
PO without unwanted effects on the hematocrit (7).
onversely, this might limit the extent of tissue protection,
nd higher doses might be necessary to render optimal
ardiac protection.
Therefore, a nonhematopoietic derivate of EPO (the so
alled asialoerythropoietin [asialoEPO]) has been devel-
ped. AsialoEPO is produced by removing the sialic acid
oieties from the EPO molecule, which are responsible for
ts delayed clearance in vivo (8). This modification renders
sialoEPO a very short half-life, insufficient to significantly
timulate the hematopoiesis. However, only brief exposure
o EPO is needed for tissue-protective effects (9). In a study
erformed by Erbayraktar et al. (10), asialoEPO exhibited
europrotective effects in different experimental models of
rain and spine injury, without an effect on hemoglobin
evels. This concept was further validated in other tissues,
ncluding kidneys. Administration of asialoEPO protected
gainst renal ischemia-reperfusion injury, possibly through
echanisms involving inhibition of apoptosis (11). In this
ssue of the Journal, Ogino et al. (12) demonstrate for the
rst time cardioprotective effects of asialoEPO as well. In
heir study, asialoEPO attenuated nephrectomy-induced
eft ventricular remodeling and dysfunction. This under-
cores that the improvement of cardiac function is not
ediated through increased hemoglobin levels but through
leiotropic effects. In this light, the authors show that
sialoEPO inhibited fibrosis, inflammatory changes, and
xidative damage. Furthermore, treatment with asialoEPO
esulted in an improved capillary density, providing an
ttractive mechanism for cardioprotection in heart failure
13). Our group has previously shown that EPO-induced
eovascularization is associated with improved cardiac per-
ormance in a post-myocardial infarction model (14). This
ffect is partly mediated through stimulation of endothelial
rogenitor cells from the bone marrow as well as induction
f myocardial vascular endothelial growth factor expression
15). Interestingly, in an ischemic hind limb model, asialo-
PO enhanced angiogenesis through a stimulating effect on
one marrow cells (16).
A different approach to avoid hematopoietic effects of
PO and preserve tissue protection is to use derivates with
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Asialoerythropoietin in HF November 30, 2010:1959–60ifferent affinity to the EPO receptor. Carbamylated eryth-
opoietin (CEPO) is an EPO derivate that does not bind to
omodimeric EPO-receptor, mediating hematopoiesis. In-
tead, CEPO activates a heteroreceptor complex consisting
f both the EPO receptor and beta-common receptor
ubunit, which is expressed in numerous organs, including
eart and kidney (17). CEPO has proven its effects already
n experimental myocardial injury. In rats subjected to
schemia-reperfusion injury CEPO treatment reduced myo-
ardial cell loss and improved left ventricular function,
ithout any effect on the hematocrit (18).
Thus, the idea of EPO-mediated cardioprotection with-
ut the undesirable increase in hemoglobin levels seems
ttractive for clinical use, and it might indeed be possible to
un with the hare and hunt with the hounds. However,
uture clinical studies are needed to support this concept
rom “bench to bedside.”
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